2012 ACR/ARHP ANNUAL MEETING. session

Transcription

1 2012 ACR/ARHP ANNUAL MEETING session T R A C K E R Pre-meeting Courses: November 9-10, 2012 opening lecture and awards: November 10, 2012 opening event: November 10, 2012 Scientific Sessions: November 10-14, 2012

2 Call for Proposals and Study Group Applications Submission Deadline: Friday, December 14, 2012 at noon. This is your opportunity to share your ideas and make a contribution to the 2013 Annual Meeting. To view instructions and submit a session proposal, visit Coordinate a study group and create a unique networking opportunity for your colleagues. To view the guidelines and submit an application, visit

3 session T R A C K E R U se the Session Tracker to record your as you go, then use My CME Tracker as a guide to apply for at and obtain a certificate for your records. Educational Tracks Look for these icons to navigate the meeting by track: BASIC SCIENCE CLINICAL SCIENCE CLINICAL PRACTICE BUSINESS/ ADMINISTRATION PM PAIN MANAGEMENT PS PATIENT SAFETY Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: The ACR designates this live educational activity for a maximum of AMA PRA Category 1 credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. International Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s), must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and address. The information will be used to verify your meeting attendance. The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit to EACCME credit should contact the UEMS. Health Professionals: Participants may claim hours to receive a Certificate for an activity designated for AMA PRA Category 1 Credit(s). For non-cme sessions, attendees may also request a certificate of participation. 1

4 2012 ACR/ARHP ANNUAL MEETING IMPORTANT LOCATIONS ACR Office...102A; Telephone: (202) Attendee Lounge...Ballroom Pre-Function Business Center...L Street South Lobby (under escalator) Career Connection...Exhibit Hall (Hall A), Booth 945 Child Care... Call for Location; Telephone: (202) CME/Internet Center...Concourse (near entrance to Hall A) Coat/Baggage Check...Registration (Salons G-H-I) Exhibit Hall...Hall A First Aid...Exhibit Hall (Hall A, bottom of escalator) Graffiti Walls...Exhibit Hall (Hall A) & Grand Lobby Hotel Reservations...Registration (Salons G-H-I) Industry-Supported Symposia Information...L Street South Lobby (under escalator) Innovation Theater...Hall A, Booth 1451 Lost and Found...ACR Office (102A) Membership Booth...Registration (Salons G-H-I) Newsroom...203A-B; Telephone: (202) Nursing Mothers Room...Salon D Poster Hall...Hall B Prayer Room...Salon E (East Building, Street Level) Recharge Areas... Exhibit Hall (Hall A, main aisles), Attendee Lounge (Ballroom Pre- Function) and large meeting rooms Registration...Salons G-H-I (Level 1) Resource Center...L Street Bridge (Level 2) Restaurant Reservations...Grand Lobby Rheumatology Research Foundation 5K Run/Walk Registration...Registration (Salons G-H-I) Rheumatology Research Foundation Booth...L Street Bridge (Level 2) Rheumatology Research Foundation Donors Lounge...East Overlook (2nd Floor) 2

5 session T R A C K E R Ribbon Distribution...Registration (Salons G-H-I) SessionSelect Lounge...West Overlook (2nd Floor) Shuttle Bus...L Street Speaker Lounge Speaker Ready Room Visitor Information...Grand Lobby Wheelchairs (complimentary-limited availability)...information Desk (Grand Lobby) Wi-Fi Way...Exhibit Hall (Hall A) Special Needs If you require special arrangements, please contact the ACR Office (102A); Telephone: (202) Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder. Printing of this publication is supported by Amgen, Inc. 3

6 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance FRIDAY & SATURDAY, NOVEMBER 9-10 friday, November 9, :30 am Pre-meeting Courses 7:30 am 5:30 pm 9:00 am 5:00 pm 1:00 1:00 5:55 pm 1:00 ACR/ARHP Registration... Registration Hall (Salons G-H-I) ACR Musculoskeletal Ultrasound Course for Rheumatologists Day One A 8.5 hrs ACR Certified Rheumatology Coder Course: Unlock the Mystery: A Roadmap for Rheumatology Coding Day One PM B ACR/ABIM Maintenance of Certification Learning Session 2012 Update in Rheumatology C ACR Basic Research Conference: Mesenchymal Cells in Rheumatic Diseases: Tissue Erosion/Invasion vs. Fibrosis Day One of Two... Ballroom A 4.5 hrs ACR Clinical Research Conference: Pain Research: New Methods and Challenges Day One... Ballroom C 4.5 hrs saturday, November 10, :30 am 6:30 pm Pre-meeting Courses 7:15 am 4:30 pm 8:00 am 4:00 pm 8:00 am 4:30 pm 8:00 am 4:30 pm ACR/ARHP Registration... Registration Hall (Salons G-H-I) ACR Musculoskeletal Ultrasound Course for Rheumatologists Day Two of Two A 8.0 hrs ACR Review Course... Hall D ACR Basic Research Conference: Mesenchymal Cells in Rheumatic Diseases: Tissue Erosion/Invasion vs. Fibrosis Day Two of Two... Ballroom A ARHP Clinical Focus Course: Treating the Patient with Osteoarthritis: Interventions, Innovations and Clinical Insights: Introduction A 6.0 hrs 5.75 hrs 7.5 hrs 4

7 session T R A C K E R SATURDAY & SUNDAY, NOVEMBER Meeting At-A-Glance 8:00 am 4:30 pm 8:30 am 4:15 pm 11:00 am 5:00 pm 4:30 6:15 pm 7:00 10:00 pm CORC Pre-meeting Course for Practice Managers: Helping You Manage A Profitable Practice PM A 7.5 hrs ACR Clinical Research Conference: Pain Research: New Methods and Challenges Day Two of Two... Ballroom C 6.25 hrs ACR Certified Rheumatology Coder Course Examination: Unlock the Mystery: A Roadmap for Rheumatology Coding Day Two of Two PM B ACR/ARHP Opening Lecture and Awards Straight and Swift to My Wounded I Go: The Reality of Civil War Medicine... Hall D ACR/ARHP Opening Event... Newseum 0.75 hrs sunday, November 11, :30 am 6:00 7:30 am 7:30 8:30 am 7:30 9:00 am 7:45 9:00 am ACR/ARHP Registration... Rheumatology Research Foundation 5K Run/Walk Modifying Causal Risk Factors that Influence the Incidence of Falls by Older Adults... Year in Review... Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis Tips for Publishing Your Work in a Peer Reviewed Medical Journal... Registration Hall (Salons G-H-I) 146 C Hall D 204 A 207 A ARHP Sessions ARHP First-time Attendee Orientation ARHP Moderators Orientation hrs 5

8 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance SUNDAY, NOVEMBER 11 7:45 9:15 am ACR Meet the Professor Sessions Behçet s Disease (001)... Controversies in Sjögren s Syndrome (002)... Infections with Biologics (003)... Pediatrics: Dermatomyositis (004)... Pediatrics: Difficult to Treat Juvenile Idiopathic Arthiritis (005)... Rheumatoid Arthritis: Biological Agents (006) Spondylarthropathy: An Update (007)... Systemic Arthritis and Still s Disease (008)... Lupus Erythematosus: Central Nervous System (009)... Vasculitis Mimics (010) A 154 B A 158 B 159 A 159 B 160 7:45 9:45 am ACR Workshops Basic Statistical Concepts for the Medical Researcher (201)... Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (202)... Dermatopathology of Rheumatic Diseases (203)... Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (204) A 144 C 144 A 144 B 2.0 hrs 9:00 10:00 am Advances in the Biology of Aging... CORC FORUM: Achieving Economic Goals in an Era of Healthcare Reform... New Therapies for Modulating Signaling in Rheumatoid Arthritis... The Plasticity of T Regulatory Cells and their Role in Autoimmunity... Update on Stroke B 147 A Hall E 152 A Hall D 1.0 hr 9:00 10:30 am Extra-articular Involvement in Rheumatoid Arthritis... Medical Education: The Year in Review B 145 A 6

9 session T R A C K E R SUNDAY, NOVEMBER 11 Meeting At-A-Glance 9:00 am ACR Poster Session A and Poster Tours... Abstracts (#1-724) Poster Presentations 9:00 11:00 am Poster Tours 9:00 9:45 am 301 Fellows Only: How to Navigate the Poster Hall 302 Osteoarthritis: Clinical Aspects 303 Pediatric Rheumatology: Clinical Aspects 304 Rheumatoid Arthritis: Clinical Aspects 305 Rrheumatoid Arthritis: Treatment: Small Molecules, Biologics and Gene Therapy 306 Systemic Lupus Erythematosus: Clinical Aspects 10:15 11:00 am 307 Osteoarthritis - Clinical Aspects 308 Rrheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy 309 Rheumatoid Arthritis: Clinical Aspects 310 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment 311 Systemic Lupus Erythematosus: Clinical Aspects Poster Hall (Hall B) 2.0 hrs 9:30 10:30 am 10:00 11:00 am ARHP Session Keynote Address: It s Not Child s Play: Growing Up With and Mastering Juvenile Idiopathic Arthritis from the Child s Perspective C Rheumatology Research Foundation Special Session Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn t Built in a Day: New Insights into Destruction and Repair in Rheumatic Disease... Ballroom B 1.0 hr 1.0 hr 10:00 am 5:00 pm Exhibits... Exhibit Hall Morning Snack Break (10:00 11:00 am) Exhibit Hall Afternoon Snack Break (2:00 3:00 pm) Innovation Theater... (10:30 11:15 am and 2:30 3:15 pm) See page 29 for the list of presentations. Exhibit Hall (Hall A) Exhibit Hall (Hall A) Booth # :30 am 12:30 pm ACR Workshops Adult Musculoskeletal Upper Examinations (205)... Musculoskeletal Ultrasound (206)... Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (207) C 144 B 149 A 2.0 hrs 7

10 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance SUNDAY, NOVEMBER 11 11:00 am 12:30 pm 11:00 am noon 12:30 1:45 pm 12:30 2:15 pm ACR Plenary Session I Discovery 2012 Abstracts (# )... ARHP Sessions Hands: Non-Surgical Management and Bracing What You Don t Know Can Hurt You... New Medication Developments in Rheumatology... Rheumatic Disease Update: Vasculitis... The 5A Approach to Physical Activity Counseling for Arthritis Patients... Hall D A 204 A 201 ACR Session ACR Knowledge Bowl Preliminary Round B ARHP Networking Event ARHP Networking Forum... Renaissance Washington Renaissance Ballroom, East & West 1.0 hrs 1.25 hrs 12:45 2:15 pm 1:00 2:00 pm ACR Meet the Professor Sessions Adult Inflammatory Myopathy (011)... Cutaneous Vasculitis (012)... Inflammatory Eye Disease/Uveitis (013)... Myopathy: Issues in Diagnosis and Treatment (014)... Osteoporosis: Novel Treatments (015)... Pediatrics: Periodic Fevers in Children (016)... Polymyalgia Rheumatica (017)... Pregnancy in Rheumatic Diseases (018)... Systemic Lupus Erythematosus: Novel Treatments (019)... Vitamin D and Bone Health (020)... Endoplasmic Reticulum Stress Unfolded Protein Response in Immunity and Inflammation... Mechanisms of Pain in Rheumatic Diseases... Preoperative Assessment and Perioperative Management of the Patient with Rheumatic Disease: What Every Rheumatologist Should Know (Clinical Review) A 154 B A 158 B 159 A 159 B A 146 C Hall E 1.0 hrs 8

11 session T R A C K E R SUNDAY, NOVEMBER 11 Meeting At-A-Glance 1:15 3:15 pm 2:30 4:00 pm 2:30 4:00 pm ACR Workshops Designing a Website for Your Practice (208)... Muscle Involvement in Rheumatic Diseases (209)... Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (210)... Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (211)... Complementary and Alternative Medicine: Evidence Based Options for Arthritis Patients PM... Prospects for Prevention and Cure of Rheumatoid Arthritis... The Great Debate: In 2012 what are the Roles of Cyclophosphamide versus Rituximab in ANCA-Associated Vasculitis... Update on Treatment of Systemic Lupus Erythematosus.. ACR Concurrent Abstract Sessions (# ) Biology and Pathology of Bone and Joint: Osteoarthritis... (# ) Cytokines, Mediators, and Gene Regulation I Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk I... (# ) Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease... (# ) Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes... (# ) Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies (# ) Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I... (# ) Rheumatoid Arthritis Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis... (# ) Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis... (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Spondyloarthritis I... (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics B 144 A 144 C 149 A Ballroom A Salon B Hall D Hall E 150 B 147 A 202 B 145 A 152 A 207 A Ballroom C Renaissance Washington Grand Ballroom North Ballroom B 146 C 2.0 hrs 9

12 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance SUNDAY, NOVEMBER 11 2:30 4:00 pm ARHP Sessions Non-pharmacological Management of Fibomyalgia: Your Toolbox PM... Practice Managers: Improving Access and Website Marketing (Practice Management Series)... Rheumatic Disease Update: Inflammatory Eye Disease A 204 A 206 2:30 4:00 pm ARHP Concurrent Abstract Sessions (# ) Foot and Gait Disorders... (# ) Osteoarthritis A 201 4:00 ACR Workshops Dermatopathology of Rheumatic Diseases (212)... Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back (213)... Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (214)... Synovial Fluid Analysis and Crystal Identification (215) A 144 B 144 C 149 A 2.0 hrs 4:30 Classification and Treatment of Sjögren s Syndrome... Metabolic Abnormalities in Autoimmunity... Puberty, Adolescence and Rheumatologic Disease... Thieves Market: Show Me Your Best Cases Update on Psoriatic Arthritis and the Spondylarthropathies... Ballroom C 143 A 207 A Hall D Hall E 10 4:30 ACR Concurrent Abstract Sessions (# ) Fibromyalgia and Soft Tissue Disorders I... (# ) Imaging of Rheumatic Diseases I: Ultrasound and X-ray... (# ) Metabolic and Crystal Arthropathies: Clinical... (# ) Osteoporosis and Metabolic Bone Disease... (# ) Rheumatoid Arthritis Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies... (# ) Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities... (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment I: Renal... (# ) Systemic Lupus Erythematosus Human Etiology and Pathogenesis I... (# ) Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics I... (# ) Vasculitis: Pathogenesis B Salon B 152 A 150 B Renaissance Washington Grand Ballroom North Ballroom A Ballroom B 145 A 146 C 147 A

13 session T R A C K E R SUNDAY & MONDAY, NOVEMBER Meeting At-A-Glance 4:30 4:30 4:30 6:30 9:30 pm ACR Meet the Professor Sessions Ankylosing Spondylitis: 2012 Update (021)... Antiphospholipid Syndrome (022)... Crystal: Diagnosis and Management of Gout (023)... Immunodeficiency Syndromes (024)... Pain: Evaluation and Treatment of Back Pain (025) PM... Psoriatic Arthritis (026)... Pulmonary Hypertension in the Rheumatic Diseases (027)... Rheumatoid Arthritis: Challenging Cases (028)... Rheumatoid Arthritis: Outcome Measures in Clinical Practice (029)... Temporal Arteritis (030)... ARHP Sessions Income Inequities Are Perilous to People with Arthritis Practice Management: Patients As Partners in Design and Delivery (Practice Management Series)... ARHP Concurrent Abstract Sessions (# )Pediatrics: Disease Flares... (# ) Psychological Aspects of Rheumatologic Disease Industry-Supported Symposia See program book for the list of symposia A 154 A A 158 B 159 A 159 B A A MONDAY, November 12, :30 am 7:30 8:30 am ACR/ARHP Registration... Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis... Cross-Sectional Imaging Techniques for Rheumatology... Immune Tolerance: From Theory and Clinical Practice Hench Lecture: Synovial Immunobiology and Response to Therapy in Rheumatoid... Registration Hall (Salons G-H-I) Hall D Renaissance Washington Grand Ballroom North Ballroom A Salon B 1.0 hrs 11

14 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance MONDAY, NOVEMBER 12 7:30 8:30 am 7:30 9:00 am 7:45 9:15 am 7:45 9:45 am 9:00 10:00 am ARHP Sessions Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care (Arthroplasty/Joint Replacement Series) PS... Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice PS... Infusion Room Information for Medical Professionals (Infusion Series)... New and Better Habits! Facilitating Patient Self-management with Proven Behavior Change Strategies PS A 143 A ACR Session ILAR The Current Rheumatology Workforce Across the Globe B ACR Meet the Professors Sessions Crystal: Diagnosis and Management of Gout (031)... Osteoarthritis: Update 2012 (032)... Pediatric Rheumatology for Adult Rheumatologists (033)... Pediatrics: Spondylarthritis in Children (034)... Psoriatic Arthritis (035)... Rheumatoid Arthritis: Difficult Cases (036)... Rheumatoid Arthritis: Difficult Cases (037)... Scleroderma: Systemic Sclerosis (038)... Scleroderma: Systemic Sclerosis (039)... Vasculitis: Update (040)... ACR/ARHP Workshops Joint Injections (Knee and Ankle Prosthetics) (216)... Musculoskeletal Ultrasound (217)... Peripheral Magnetic Resonance Imaging in Rheumatology Practice (218)... X-ray Challenges in Rheumatic Diseases (219)... Epigenetic Factors in Autoimmune Disease... New Anticoagulants: What a Hematologist Thinks a Rheumatologist Needs to Know! A 154 B A 158 B 159 A 159 B C 144 B 144 A 149 A 152 A Hall D Rheumatology Research Foundation Special Session Memorial Lectureship: Pathogenesis of Rheumatoid Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Destruction... Hall E 1.0 hrs 2.0 hrs 1.0 hrs 12

15 session T R A C K E R MONDAY, NOVEMBER 12 Meeting At-A-Glance 9:00 10:00 am 9:00 10:30 am ARHP Sessions Clinical Trials: Participation and Recruitment... Infusion Reactions: Management and Prevention (Infusion Series)... Issues in the Management of Rheumatic Disease in Patients Undergoing Joint Replacement (Arthroplasty/Joint Replacement Series)... Rheumatic Disease Update: Gout... Creating an Efficient Rheum Practice... Legislative Update from Capitol Hill... Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond PS A 204 A B 147 A 207 A 1.0 hrs 9:00 10:30 am Rheumatology Research Foundation Special Session Clinician Scholar Educator Presentations A 9:00 am ACR/ARHP Poster Session B, Thieves Market and Poster... Tours Abstracts (# ) Poster Presentations 9:00 11:00 am Poster Tours 9:00 9:45 am 312 ARHP Patient Care and Clinically-Focused Research 313 Orthopedics, Low Back Pain and Rehabilitation 314 Rheumatoid Arthritis: Clinical Aspects 315 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment 316 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s: Clinical Aspects and Therapeutics 317 Vvasculitis 10:15 11:00 am 318 Fibromyalgia and Soft Tissue Disorder 319 Osteoarthritis - Clinical Aspects 320 Rrheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy 321 Rheumatoid Arthritis: Clinical Aspects 322 Systemic Lupus Erythematosus: Clinical Aspects 323 Rheumatology Research Foundation - Health Services/ Outcomes Research Poster Hall (Hall B) 2.0 hrs 13

16 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance MONDAY, NOVEMBER 12 10:00 am 5:00 pm Exhibits... Exhibit Hall Morning Snack Break (10:00 11:00 am) Exhibit Hall Afternoon Snack Break (2:00 3:00 pm) Innovation Theater... (10:30 11:15 pm, 12:30 1:15 pm and 2:30 3:15 pm) See page 29 for the list of presentations. Exhibit Hall (Hall A) Exhibit Hall (Hall A) Booth # :30 11:30 am ARHP Session Distinguished Lecturer: Unraveling the Go-Gene hrs 10:30 am 12:30 pm ACR Workshops Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (220)... Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (221) B 144 A 2.0 hrs 11:00 am 12:30 pm ACR Plenary Session II: Discovery 2012 (Abstracts # )... Hall E 11:00 am 12:30 pm noon 2:00 pm ACR Knowledge Bowl Final Round... Career Opportunities in Rheumatology: Making a Choice New Developments in Systemic Juvenile Idiopathic Arthritis Management... The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization PS... ARHP Networking Event ARHP Networking at Noon... Hall D 147 A Ballroom C 152 A Renaissance Washington Renaissance Ballroom, East & West 14

17 session T R A C K E R MONDAY, NOVEMBER 12 Meeting At-A-Glance 12:45 2:15 pm 1:00 2:00 pm 1:15 3:15 pm 2:30 4:00 pm ACR Meet the Professors Sessions Ankylosing Spondylitis: 2012 Update (041)... Basic Immunology for Clinical Rheumatologists (042)... Challenging Cases in Osteoporosis Management (043)... Dermatological Manifestations of Rheumatic Diseases (044) Hereditary Angioderma (045)... Pulmonary Manifestations of Rheumatic Disease (046)... Raynaud s and Digital Ischemia (047)... Scleroderma Mimics (048)... Vaccinations for Patients on Biologic Therapies (049)... Vasculitis: Update (050)... Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy: Recent Advances, Current Thoughts PM... Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools... Pediatric Rheumatology Town Hall Meeting... Scleroderma Bowel Disease: From Top to Bottom (Clinical Review)... ACR/ARHP Workshops Histopathology of Vasculitis (222)... Joint Injections (Shoulder and Wrist Prosthetics) (223)... MRI in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (224)... Curbside Consults Ask the Professors... Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis... Mechanotransduction in Bone and Cartilage... Neuropsychiatric Lupus in Children and Adolescents... Osteoporosis: From Bisphosphonates and Beyond A 154 B A 158 B 159 A 159 B 160 Ballroom A 152 A 201 Hall E 149 B 144 C 144 B Hall D Renaissance Washington Grand Ballroom North 152 A Ballroom C Ballroom A 1.0 hrs 2.0 hrs 15

18 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance MONDAY, NOVEMBER 12 2:30 4:00 pm 2:30 4:00 pm 4:00 ACR Concurrent Abstract Sessions (# ) Cell-cell Adhesion, Cell Trafficking and Angiogenesis Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk II... (# ) Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease... (# ) Genetics and Genomics of Rheumatic Diseases (# ) Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging... (# ) Infection-related Rheumatic Disease... (# ) Metabolic and Crystal Arthropathies: Basic Science... (# ) Rheumatoid Arthritis Animal Models... (# ) Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Safety I... (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy... (# ) Vasculitis: Clinical Trials... ARHP Sessions Demystifying the Study Section: How Grants Are Reviewed and Scored... Depression in Rheumatic Diseases... Minimizing Falls in Geriatric Rheumatic Populations... Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes through Examination of Patient Factors, Practice Variation and Best Practice Recommendations (Arthroplasty/ Joint Replacement Series)... ACR Workshops Getting Electronic Health Record Right (225)... Musculoskeletal Ultrasonography: Basic (226)... Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data 3 and Beyond toward a Standard, Scientific, Quantitative Patient History (227)... Systemic Sclerosis: How to Perform Skin Scores (228) A Salon B 145 A 202 B 150 B 147 A 207 A Hall E Ballroom B 146 C 143 A 204 A B 144 B 144 A 144 C 2.0 hrs 16

19 session T R A C K E R MONDAY, NOVEMBER 12 Meeting At-A-Glance 4:30 Aging and the Rheumatic Diseases... Dermatology Topics for Rheumatologists: What You Need to Know... Energetics, Metabolism and Osteoarthritis... Gout and Hyperuricemia: Diseases Beyond the Joint... Preclinical Autoimmunity Potential for Prevention B Hall D 152 A Salon B Ballroom C 4:30 ACR Concurrent Abstract Sessions (# ) Cytokines, Mediators, and Gene Regulation II (# ) Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment (# ) Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies... (# ) Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II... (# ) Rheumatoid Arthritis Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease... (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis (# ) Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Safety II... (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Spondyloarthritis II... (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment III: Cardiovascular... (# ) Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics II A Ballroom B 202 B 207 A Ballroom A 146 C Hall E 145 A Renaissance Washington Grand Ballroom North 147 A 17

20 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance MONDAY, NOVEMBER 12 4:30 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (051)... Antiphospholipid Syndrome (052)... Controversies in Sjögren s Syndrome (053)... Dermatological Manifestations of Rheumatic Diseases (054)... Fibromyalgia and Dysautonomia (055)... Pain: Evaluation and Treatment of Back Pain (056) PM... Pediatric Systemic Lupus (057)... Psoriatic Arthritis (058)... Rheumatoid Arthritis: Biological Agents (059)... Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (060) A 154 B A 158 B 159 A 159 B 160 4:30 ARHP Sessions Early Rehabiliation for Hip and Foot Osteoarthritis: Opportunities and Challenges... Novel Approaches to Pain Management in Juvenile Idiopathic Arthritis PM... Promoting Participation: Where Is the Field and Where Do We Go Next? A 143 A 4:30 ARHP Concurrent Abstract Session (# ) Care of Patients with Rheumatoid Arthritis

21 session T R A C K E R MONDAY & TUESDAY, NOVEMBER Meeting At-A-Glance 6:45 7:45 pm ACR Study Groups ACR-EULAR Study Group Signal Transduction in the Rheumatic Diseases... Antiphospholipid Syndrome... Autoantibodies in Diagnosis and Follow-up of Rheumatic Diseases... Childhood Vasculitis... Clinical Research Methodology... Degos Disease and Other Atypical Vasculopathies... Geriatric Rheumatology... Global Health Initiatives... Gout Classification Criteria... Hypermobility... Interstitial Lung Disease... (JAW) Juvenile Arthritis Workgroup... Macrophage Activation Syndrome... Musculoskeletal Ultrasound... Myositis: New Developments on Myositis Therapies... Neuro Endocrine Immunology... Osteoarthritis Synovial Inflammation... Pediatric Rheumatologists Interested in Medical Education... Pediatric Rheumatology Imaging... Skin A 147 A 150 B 152 A 158 A 159 B 158 B A 204 A 154 B 146 C 207 A 202 B 140 A 154 A A 148 TUESDAY, November 13, :30 am 7:30 8:30 am 7:30 8:30 am ACR/ARHP Registration... Chronic Recurrent Multifocal Osteomyelitis... Molecular and Cellular Basis of Tissue Homing... Update on Immune Mediated Glomerular Disease... Registration Hall (Salons G-H-I) Ballroom B 152 A Hall D Rheumatology Research Foundation Special Session Paul Klemperer, MD Memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting Outcomes... Ballroom C 1.0 hrs 1.0 hrs 19

22 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance TUESDAY, NOVEMBER 13 7:30 8:30 am ARHP Sessions Clinical and Epidemiologic Study Designs in Rheumatic Disease Research... Don t Let the Pink Sheets Make You Blue... Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease (Infection Series) A 145 A 1.0 hrs 7:45 9:15 am ACR Meet the Professors Sessions Ankylosing Spondylitis: Disease Modification (061)... Crystal: Diagnosis and Management of Gout (062)... Infections with Biologics (063)... Osteoarthritis: Update 2012 (064)... Pain: Dealing with Patients with Refractory Pain in Musculoskeletal and Autoimmune Disorders (065) PM... Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists (066)... Pregnancy in Rheumatic Diseases (067)... Reactive Arthritis: An Update (068)... Scleroderma: Systemic Sclerosis (069)... Vasculitis: Update (070) A 154 B A 158 B 159 A 159 B 160 7:45 9:45 am ACR/ARHP Workshops Adult Musculoskeletal Lower Examinations (229)... Knee Braces and Foot Orthosis for Knee Osteoarthritis (230).. Peripheral Magnetic Resonance Imaging in Rheumatology Practice (231)... Synovial Fluid Analysis and Crystal Identification (232) C 144 A 144 B 149 A 2.0 hrs 9:00 10:00 am Advances in Targeting of B cell Survival Factors... Systems Immunology... Ballroom A 147 A 1.0 hrs 9:00 10:00 am ARHP Sessions Hepatitis in Patients with Rheumatologic Disease (Infection Series) Rheumatic Disease Update: The Approach to Low Back Pain PM... Threats to Validity: Confounding in Rheumatic Disease Research (Research Series) A 143 A hrs 20 9:00 10:30 pm Contract Negotiations for Physicians... Paradigm Shifts in Rheumatoid Arthritis... The Guide to Meaningful Use and Beyond B Hall D Renaissance Washington Grand Ballroom North

23 session T R A C K E R TUESDAY, NOVEMBER 13 Meeting At-A-Glance 9:00 10:30 am Rheumatology Research Foundation Special Session Disease Targeted Research A 9:00 10:30 am 9:00 am ARHP Concurrent Abstract Sessions (# ) Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease... (# ) Programs and Literacy in Patients with Rheumatologic Diseases... ACR/ARHP Poster Session C, Thieves Market Posters and Poster Tours... Abstracts (# ) Poster Presentations 9:00 11:00 am Poster Tours 9:00 9:45 am 324 ARHP Epidemiology and Public Health 325 Miscellaneous Rheumatic and Inflammatory Diseases 326 Rheumatoid Arthritis: Clinical Aspects 327 Systemic Lupus Erythematosus: Human Etiology and Pathogenesis 328 Vasculitis 10:15 11:00 am 329 Antiphospholipid Syndrome 330 Fibromyalgia and Soft Tissue Disorder 331 Metabolic and Crystal Arthropathies 332 Oosteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis 333 Sjögren s Syndrome 334 Rheumatology Research Foundation - Pathogenic Mechanisms in Rheumatic Diseases A Poster Hall (Hall B) 1.0 hrs 2.0 hrs 10:00 am 5:00 pm Exhibits... Exhibit Hall Morning Snack Break (10:00 11:00 am) Exhibit Hall Afternoon Snack Break (2:00 3:00 pm) Innovation Theater... (10:30 11:15 pm, 12:30 1:15 pm and 2:30 3:15 pm) See page 29 for the list of presentations. Exhibit Hall (Hall A) Exhibit Hall (Hall A) Booth # :30 11:30 am ACR Session Gouty Inflammation C 1.0 hrs 10:30 11:30 am ARHP Sessions Immunizations in Patients with Rheumatologic Disease (Infection Series)... Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues A hrs 21

24 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance TUESDAY, NOVEMBER 13 10:30 am noon 10:30 am 12:30 pm 11:00 noon 11:00 am 12:30 pm 11:00 12:30 pm noon 1:00 pm 12:45 2:15 pm ACR/ARHP Combined Abstract Session (# ) ACR/ARHP Combined Rehabilitation Abstract Session... ACR Workshops Histopathology of Vasculitis (233)... Joint Injection Techniques (234)... ARHP Sessions A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective... Strategies to Enhance Office Efficiencies and Access to Care in Rheumatology Practice PS... ACR Plenary Session III Discovery 2012 Abstracts (# )... Microbiome Influence on Autoimmunity... Polymyalgia Rheumatica Recent Advances and Ongoing Questions... Top 10 Compliance Risks Facing Physicians PS... ARHP Networking Event ARHP Networking Break... ACR Meet the Professor Sessions Basic Immunology for Clinical Rheumatologists (071)... Fibromyalgia and Dysautonomia (072)... Myopathy: Issues in Diagnosis and Treatment (073)... Rheumatoid Arthritis: Challenging Cases (074)... Rheumatoid Arthritis: Safety of Novel Therapies (075)... Systemic Lupus Erythematosus: Central Nervous System (076)... Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (077)... Systemic Lupus Erythematosus: Lupus Nephritis (078)... Temporal Arteritis (079)... Vasculitis: Update (080) A 149 B 144 C 204 A 143 A Hall E Renaissance Washington Grand Ballroom North Hall D 202 B Renaissance Washington Congressional Hall B A 154 B A 158 B 159 A 159 B hrs 1.0 hrs 22

25 session T R A C K E R TUESDAY, NOVEMBER 13 Meeting At-A-Glance 1:00 2:00 pm 1:00 2:00 pm 1:15 3:15 pm 1:30 2:30 pm 2:30 4:00 pm Catastrophic Antiphospholipid Syndrome (Clinical Review)... Osteoimmunology... ACR Study Groups A Primer on Educational Theory for Medical Educators... Capillaroscopy in Rheumatic Diseases... Crystal Group... Decision Aids... Latin American... Lupus... Magnetic Resonance Imaging... Polymyalgia Rheumatica... Scleroderma Biomarkers... Shaping the Future of Psoriatic Disease Care: Current Controversies and Progress... Sjögren s Syndrome... Veterans Affairs Rheumatology... ACR/ARHP Workshops Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (235)... MRI in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (236)... Synovial Fluid Analysis and Crystal Identification (237)... Web-based Tools for Enhancing and Managing Teaching and Clinical Practice (238)... ACR Session ACR Leadership Town Hall Meeting & Business Meeting... Approach and Management of Back Pain in Older Adults PM... Connective Tissue Disease Associated Interstitial Lung Disease... New Molecules in Joint Biology... Visualising the Immuno-inflammatory Response... Hall D Ballroom B 204 A A 146 C 140 A 202 B A 145 A 150 B 143 A 152 A 144 C 144 B 149 A 149 B Ballroom A Hall E Hall D 152 A 150 B 1.0 hrs 2.0 hrs 23

26 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance TUESDAY, NOVEMBER 13 2:30 4:00 pm 2:30 4:00 pm 2:30 4:00 pm 4:00 4:30 5:30 pm ACR Concurrent Abstract Sessions ACR Late-breaking Abstracts Session... (# ) Antiphospholipid Syndrome... (# ) Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease... (# ) Osteoarthritis Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments (# ) Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculidities... (# ) Rheumatoid Arthritis - Clinical Aspects IV: Non-biologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events... (# ) Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors... (# ) Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology... (# ) Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II... (# ) T-cell Biology and Targets in Autoimmune Disease... Ballroom A 147 A 202 B Renaissance Washington Grand Ballroom North 207 A Ballroom B Ballroom C Salon B 146 C 204 A ACR/ARHP Combined Abstract Session (# ) ACR/ARHP Combined Epidemiology Abstract Session ARHP Sessions Myositis: Pathogenesis, Diagnosis and Management... Rheumatic Disease Update: Systemic Lupus Erythematosus... Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions... Transition Tools for Patients: Pediatric to Adults... ACR Workshop Joint Injection Techniques (239) A 143 A 140 A 144 C 2.0 hrs ARHP Session Obesity: It is a Chronic Disease A 1.0 hrs 24

27 session T R A C K E R TUESDAY, NOVEMBER 13 Meeting At-A-Glance 4:30 4:30 4:30 4:30 Diagnostic Assessments in Myopathy... MicroRNA and the Rheumatic Diseases... Should Ultrasound be Used in Rheumatology Practice?.. The Great Masqueraders: Malignancies in Rheumatic Disease... ACR Concurrent Abstract Sessions (# ) Biology and Pathology of Bone and Joint: Regulation of Bone Cells... (# ) Innate Immunity and Rheumatic Disease... (# ) Miscellaneous Rheumatic and Inflammatory I (# ) Osteoarthritis Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis... (# ) Rheumatoid Arthritis Clinical Aspects V: Comorbidities in Rheumatoid Arthritis... (# ) Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics... (# ) Sjögren s Syndrome II Clinical... (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Psoriatic Arthritis... (# ) Vasculitis: Clinical Aspects... ACR Meet the Professor Sessions Central Nervous System Vasculitis (081)... Crystal: Pseudogout (082)... Pulmonary Manifestations of Rheumatic Disease (084)... Raynaud s and Digital Ischemia (085)... Rheumatoid Arthritis: Safety of Novel Therapies (086)... Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (087)... Systemic Lupus Erythematosus: Lupus Nephritis (088)... Systemic Lupus Erythematosus: Novel Treatments (089)... Vaccinations for Patients on Biologic Therapies (090)... Hall D Ballroom B Salon B 146 C A 145 A 152 A Ballroom A Hall E 207 A Ballroom C 202 B B A 158 B 159 A 159 B 160 Rheumatology Research Foundation Special Session (# ) Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients A 25

28 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance TUESDAY & WEDNESDAY, NOVEMBER 13, 14 4:30: 6:30 9:30 pm ARHP Sessions Arthritis and the Older Worker... Best Practices for Ordering Diagnostic Imaging in Evaluating Rheumatologic Conditions... The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together... Industry-Supported Symposia See program book for the list of symposia. 204 A 150 B 206 WEDNESDAY, November 14, :00 am 1:00 pm 7:30 8:30 am 7:30 8:30 am 9:00 10:30 am ACR/ARHP Registration... Registration Hall (Salons G-H-I) Immunology of Pregnancy and Impact on Autoimmune Pathogenesis Ballroom A Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease A Rheumatology Roundup: Highlights from the 2012 Annual Scientific Meeting Hall D The Unintended Consequences of Health Information Technology PS A ARHP Sessions An Introduction to Immunology... Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems (Research Series) Biosimilars Development: FDA Perspective... IgG4-Related Disease Past Lessons and Future Directions... NIAMS-Sponsored Research in Rheumatology: 2012 Highlights... Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Predictive Biomarkers: A Journey to Personalized Health Care Ballroom C Hall D 152 A Ballroom B 150 B 1.0 hrs 1.0 hrs 26

29 session T R A C K E R WEDNESDAY, NOVEMBER 14 Meeting At-A-Glance 9:00 10:30 am 9:00 10:30 am 9:00 10:30 am 11:00 am noon 11:00 am 12:30 pm ACR Concurrent Abstract Sessions (# ) B-cell Biology and Targets in Autoimmune Disease... (# ) Imaging of Rheumatic Diseases III: Computed Tomography... (# ) Medical Education... (# ) Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response... (# ) Quality Measures and Innovations in Practice Management and Care Delivery... (# ) Rheumatoid Arthritis Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis... (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis... (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment IV: Therapeutics... ARHP Sessions Forming an Education and Support Group from the Ground up... Osteoporosis: 2012 Update... ARHP Concurrent Abstract Sessions (# ) Systemic Sclerosis, Vasculitis, Crohn s and Spondyloarthropathies... (# ) Clinical and Rehabilitative Aspects of Osteoarthritis... Amyloidosis Mechanisms of Autoinflammatory Diseases... Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases... Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice A 145 A 143 A 146 C 207 A Ballroom A Salon B Hall E A 204 A Hall D 150 B Ballroom C Hall E 1.0 hrs 27

30 2012 ACR/ARHP ANNUAL MEETING Meeting At-A-Glance WEDNESDAY, NOVEMBER 14 11:00 am 12:30 pm ACR Concurrent Abstract Sessions (# ) Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treat-to-Target Era (# ) Fibromyalgia and Soft Tissue Disorders II... (# ) Orthopedics, Low Back Pain, and Rehabilitation (# ) Pediatric Rheumatology Pathogenesis and Genetics... (# ) Rheumatoid Arthritis Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis... (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies... (# ) Sjögren s Syndrome I Pathogenesis... (# ) Systemic Lupus Erythematosus Animal Models... (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment V: Clinical Aspects A 202 B 145 A 143 A Ballroom A 146 C 147 A 152 A Ballroom B 11:00 am 12:30 pm 11:00 am 12:30 pm ARHP Sessions Highlights from the 2012 ARHP Sessions... Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis... ARHP Concurrent Abstract Sessions (# ) Factors Associated with Rheumatoid Arthritis (# ) Systemic Lupus Erythematosus A 204 A 1:00 4:00 pm Industry-Supported Post Conference Symposia See program book for the list of symposia. 28

31 session T R A C K E R Innovation Theater These non-cme accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. All Innovation Theater presentations will be held in Hall A (Booth #1451) at their designated time. 10:30-11:15 am Sunday, November 11, 2012 ACTEMRA Monotherapy: From Clinical Trial Experience to Clinical Practice Presented by Genentech, a member of the Roche Group 2:30-3:15 pm Role of Multi-Biomarker Test in RA Patient Management Presented by Crescendo Bioscience Monday, November 12, :30-11:15 am Rituxan RA - Pivotal and Long-term Efficacy and Safety Data Presented by Genentech, a member of the Roche Group Tuesday, November 13, :30-11:15 am Evaluation of Clinical Endpoints for SLE Disease Activity in Worldwide Clinical Trials: Optimization of Treatment Effects through Targeted Training and Centralized Data Review Presented by ReSearch Pharmaceutical Services, Inc. 12:30-1:15 pm Are You Using Your Father s Prednisone to Treat Your Mother s RA?: New Understanding of a Familiar Therapy Presented by Horizon Pharma 2:30-3:15 pm Pathophysiology of Pain: Processes, Plasticity, and Perception Presented by Lilly USA, LLC 12:30-1:15 pm Introducing an Innovative New Patient Educational and Support Program Presented by Janssen Biotech, Inc. 2:30-3:15 pm Case Studies: Practical Management of Gout Presented by Takeda Pharmaceuticals 29

32 2012 ACR/ARHP ANNUAL MEETING MAP conference center Lower Level Halls A, B & C 1 Exhibit Hall Career Connection First Aid Graffiti Wall Innovation Theater Recharge Stations Wi-Fi Way 2 Poster Hall Poster Service Center Poster Tours

33 session T R A C K E R Concourse Halls A, B & C conference center MAP 1 CME/Internet Center 1 31

34 2012 ACR/ARHP ANNUAL MEETING MAP conference center Street Level Grand Lobby/Registration/Salons A I Meeting Rooms & ACR Office Lost and Found 2 Business Center Industry-Supported Symposia Information 3 Metro Station 4 Nursing Mothers Room 5 Prayer Room 6 Registration Coat/Baggage Check Hotel Reservations Membership Booth Rheumatology Research Foundation 5K Run/Walk Registration Ribbon Distribution 7 Speaker Lounge 8 Speaker Ready Room 9 Visitor Information Graffiti Wall Restaurant Reservations Wheelchairs (complimentarylimited availability) RETAIL

35 session T R A C K E R Level Two Halls D & E Meeting Rooms East and West Overlook 4 conference center MAP 5 1 Newsroom 2 Opening Lecture and Awards 3 Resource Center Rheumatology Research Foundation Booth 4 Rheumatology Research Foundation Donor s Lounge 5 SessionSelect Lounge 1 GRAND LOBBY BRIDGE

36 2012 ACR/ARHP ANNUAL MEETING MAP conference center Level Three Ballrooms 1 Attendee Lounge Recharge Stations 2 Late-breaking Abstract Presentations Town Hall and Business Meeting

37 session TRA C K ER conference center MAP Exhibit Hall Hall B 1 CME/Internet Center 1 See following spread for Exhibitor legend 35

38 2012 ACR/ARHP ANNUAL MEETING MAP conference center Exhibit Hall List of Exhibitors BOOTH EXHIBITOR S Dawn Clinical Software 1005 Abbott 214 ACP/Annals of Internal Medicine 924 ACR Simple Tasks 1045 Actelion Pharmaceuticals 420 Aesku Inc 1049 American Regent, Inc. 900 Amgen, Inc. 707 Amgen, Inc. and Pfizer Inc. 304 Arthritis Foundation 413 Arthritis Health Monitor TV , 658 Autoimmune Diseases Association Auxilium Pharmaceuticals 658 Auxilium Pharmaceuticals 512 Besse Medical 438 BioMed Central 422 Bioventus LLC 1252 Bristol-Myers Squibb 206 British Society for Rheumatology 1513 Buzzy4Shots.com 1519 Cardinal Health 819 Celgene Corporation 843 Cellestis, a QIAGEN Company 361 Celltrion Healthcare Co., Ltd. 761 Chugai Pharmaceutical Co., Ltd. 221 Cleveland Clinic Clinical and Experimental Rheumatology ContextMedia: Health s Rheumatoid Health Network 748 Corinthian Reference Lab 1509 CORRONA, Inc Crescendo Bioscience, Inc CuraScript SD 639 CVS/Caremark Speciality Pharmacy 1153 DePuy Mitek 1614 DynaMed/EBSCO Publishing 357 eclinicalworks 902 Elsevier, Inc Esaote North America 506 Euroimmun US 315 European League Against Rheumatism (EULAR) 1142 Exhibitchek 514 Ferring Pharmaceuticals Inc. 641 Fidia Pharma USA 747 Forest Pharmaceuticals, Inc. 741 GE Healthcare 507 Genentech and Roche 1146 Genzyme, a Sanofi Company 537 Gilead Sciences, Inc GlaxoSmithKline 205 Gout & Uric Acid Education Society (GUAES) 738 Hattiesburg Clinic 1518 HealthWell Foundation 940 Hologic 545 Horizon Pharma, Inc. 744 Hospira 319 Hospital for Special Surgery HRA Healthcare Research & Analytics Human Genome Sciences, Inc. 746 Immco Diagnostics, Inc. 956 Inova Diagnostics, Inc Intellogics 339 JAMA Network 1023, 1226 Janssen Biotech 801 Johns Hopkins Arthritis Center 318 Journal of Rheumatology, The 857 LabCorp 601 La Lettre Du Rhumatologue - Edimark Santé 212 Letter to Editor Rheumatology 1327 Lilly USA, LLC. 853 Lippincott, Williams and Wilkins 452 Lone Oak Medical Technology 1043 Lupus Initiative, The 36

39 session T R A C K E R Exhibit Hall List of Exhibitors conference center MAP BOOTH EXHIBITOR 740 Mayo Clinic 1515 McKesson Specialty Health 847 medac pharma, Inc. 327 MedImmune, LLC 1537 Merck 308 METEOR 849 Metro Medical Supply 418 Metroplex Clinical Research Center 310 Myositis Association, The National Data Bank for Rheumatic Diseases National Fibromyalgia Partnership, Inc. National Institute of Arthritis and Musculoskeletal and Skin Diseases National Scleroderma Core Centers Northwestern University Division of Rheumatology Novartis Pharmaceuticals Corporation 618 Nutramax Laboratories, Inc. 321 NYU Langone Medical Center NYU Hospital for Joint Diseases 207 OMERACT 1305 Optasia Medical, Inc 404 Oxford University Press 313 PANLAR 1404 PatientPoint 423 Pfizer, Inc. 724 Pfizer, Inc Pulmonary Hypertension Association Questcor Pharmaceuticals, Inc. 407 Quidel Corporation 219 R. J. Fasenmyer Center for Clinical Immunology 619 RDL Reference Laboratory Regeneron Pharmaceuticals, Inc. ReSearch Pharmaceutical Services Rheumatoid Patient Foundation 1439 Rheumatology News 309 Rheumatology Nurses Society 1437 Rheumatology Practice News 825 Rottapharm Ltd 645 Sanofi Biosurgery 343 Savient Pharmaceuticals 320 Scandinavian Journal of Rheumatology 946 Siemens Medical Solutions USA Inc. 736 Silver Ring Splint Company 204 Sjogrens Syndrome Foundation 944 SNBL 1253 SOBI 501 SonoSite 314 Spondylitis Association of America 436 Springer 1261 Takeda Pharmaceuticals 410 The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 337 TheraTest Laboratories, Inc. 845 Trimer Biotech, LLC 414 TSI Healthcare 1137 UCB, Inc. 415 United Regional Health Care System 519 UpToDate 307 US Pain Foundation Inc 649 Value-Based Care in Rheumatology 312 Vasculitis Foundation 353 Vindico Medical Education 211 Organization of Teratology Information Specialists 303 Scleroderma Foundation 653 VQ OrthoCare 637 Ossur Americas 952 Oxford Immunotec Inc 412 Scott & White Healthcare 355 SI-BONE 841 Wiley Blackwell 456 Zimmer 37

40 Practicing rheumatology isn t easy. Navigating the ACR/ARHP Annual Meeting is! My Annual Meeting Everything you need, all in one place. Browse the program and search abstracts online with ease! Log-in to My Annual Meeting using your ACR/ARHP username and password to Create your itinerary View syllabi Track your CME Acquire your CME certificate Provide session feedback Open SessionSelect Check out these and other annual meeting resources at

41 Enbrel (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/ or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNFblocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months). Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months). Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patientyears of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years. Other Malignancies Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown. Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patientyears of therapy, the observed rate of melanoma was cases per 100 patient-years. Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patientyears vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin s and non-hodgkin s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 696 patients representing 1282 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Virus Reactivation Use of TNF-blocking agents has been associated with reactivation of hepatitis B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The needle cap on the prefilled syringe and on the SureClick autoinjector contains dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex. Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-todate with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions]. Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated. Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener s Granulomatosis Patients The use of Enbrel in patients with Wegener s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].

42 Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza. In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials. In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6% 8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebotreated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials Placebo Controlled a (Studies I, II, and a Phase 2 Study) Placebo (N = 152) Enbrel c (N = 349) Active Controlled b (Study III) MTX (N = 217) Enbrel c (N = 415) Reaction Percent of Patients Percent of Patients Infection (total) d Upper Respiratory Infections e Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity 1 1 a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. b Study duration of 2 years. c Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 359) Enbrel a (N = 876) Reaction Percent of Patients Infection b (total) Non-upper Respiratory Infections Upper Respiratory Infections c Injection Site 6 15 Reactions Diarrhea 2 3 Rash 1 1 Pruritus 2 1 Urticaria 1 Hypersensitivity 1 Pyrexia 1 a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. b Includes bacterial, viral and fungal infections. c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis. Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure. Adverse reactions are listed by body system below: Blood and lymphatic pancytopenia, anemia, leukopenia, system disorders: neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions] Cardiac disorders: congestive heart failure [see Warnings and Precautions] Gastrointestinal disorders: inflammatory bowel disease (IBD) General disorders: angioedema, chest pain Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases Immune disorders: macrophage activation syndrome, systemic vasculitis Musculoskeletal and lupus-like syndrome connective tissue disorders: Neoplasms benign, melanoma and non-melanoma malignant, and unspecified: skin cancers, merkel cell carcinoma [see Warnings and Precautions] Nervous system disorders: convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions] Ocular disorders: Respiratory, thoracic and mediastinal disorders: Skin and subcutaneous tissue disorders: uveitis, scleritis interstitial lung disease cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pregnancy Registry: To monitor outcomes of pregnant women exposed to Enbrel, a pregnancy registry has been established. Physicians are encouraged to register patients by calling Nursing Mothers It is not known whether Enbrel is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Enbrel, a decision should be made whether to discontinue nursing or to discontinue the drug. Pediatric Use Enbrel is indicated for treatment of polyarticular JIA in patients ages 2 years and older [see Indications and Usage, Warnings and Precautions, Adverse Reactions]. Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (<0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions]. Geriatric Use A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. Use in Diabetics There have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. Rx Only. This brief summary is based on ENBREL prescribing information v. 48: 12/2011 Manufactured by: Immunex Corporation Thousand Oaks, CA US License Number 1132 Marketed by Amgen Inc. and Pfizer Inc Immunex Corporation. All rights reserved. US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. For more information please call or visit Amgen Inc., Thousand Oaks, CA and Pfizer Inc. All rights reserved.

43 Prescription Enbrel (etanercept) is administered by injection. IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients In patients who initiated therapy at 18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin s and non-hodgkin s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants. NEUROLOGIC EVENTS Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURE Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored. HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed. HEPATITIS B VIRUS REACTIVATION Use of TNF blockers, including ENBREL, has been associated with reactivation of hepatitis B virus (HBV) in chronic carriers of this virus. The majority of these reports occurred in patients on concomitant immunosuppressive agents, which may also contribute to HBV reactivation. Exercise caution when considering ENBREL in patients identified as carriers of HBV. ALLERGIC REACTIONS Allergic reactions have been reported in <2% of patients in clinical trials of ENBREL. IMMUNIZATIONS Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin. AUTOIMMUNITY Autoantibodies may develop with ENBREL, and rarely lupuslike syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops. WEGENER S GRANULOMATOSIS PATIENTS The use of ENBREL in patients with Wegener s granulomatosis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended. MODERATE TO SEVERE ALCOHOLIC HEPATITIS Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis. ADVERSE EVENTS The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials. DRUG INTERACTIONS The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients. Please see adjacent Brief Summary of Prescribing Information. References: 1. Data on file, Pfizer Inc. 2. Klareskog L, van der Heijde D, de Jager JP, et al; for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363: Amgen Inc., Thousand Oaks, CA and Pfizer Inc. All rights reserved R4-V

44 When you have decided a biologic is the next step Choose ENBREL for appropriate moderate to severe RA patients Visit us at booth 707 ENBREL provided rapid and sustained efficacy in patients with moderate to severe RA ACR 20 Responses at Week 2, Year 1, and Year 3 (NRI) were 1 : 44%, 75%, and 52% for ENBREL + MTX* 19%, 59%, and 33% for MTX only *P<0.001 vs MTX at all timepoints NRI=Nonresponder imputation Indication ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active RA. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Important Safety Information ENBREL has been shown to increase the risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens, and should be discontinued if a patient develops a serious infection or sepsis. Test for latent TB (if positive, start treatment for TB prior to starting ENBREL) and monitor for active TB during treatment. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF) blockers, including ENBREL. Please see additional Important Safety Information and Brief Summary of Prescribing Information on the adjacent pages. TEMPO was a 3-year, multicenter, double-blind, clinical trial of 682 patients with moderately to severely active RA (mean disease duration: 7 years), who had an inadequate response to at least 1 DMARD excluding MTX. At baseline: patients were 18 years of age, MTX-naïve, had an ESR 28 mm/hr or CRP 20 mg/l, and were in ACR functional class I, II, or III. 1,2 Call ENBREL Support after you prescribe: ENBREL